Literature DB >> 404963

Pirbenicillin: comparison with carbenicillin and BL-P1654, alone and with gentamicin, against Pseudomonas aeruginosa.

C E Lopez, H C Standiford, B A Tatem, F M Calia, S C Schimpff, M J Snyder, R B Hornick.   

Abstract

Minimum inhibitory concentrations (MIC) of pirbenicillin against 135 clinical isolates of Pseudomonas aeruginosa were one-fourth of those required for carbenicillin but two times higher than those for BL-P1654. Increasing the inoculum size produced an adverse effect on the bactericidal activity for all three antibiotics. This was more apparent for pirbenicillin than for carbenicillin, but less than the effect on BL-P1654. When concentrations of antibiotics likely to be achieved clinically were used, gentamicin increased the inhibitory and bactericidal effects of all three semisynthetic penicillins for the majority of isolates. Strains highly resistant to the aminoglycoside antibiotic, however, were inhibited no more by the penicillin-gentamicin combinations than by the most effective of the antibiotics alone.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 404963      PMCID: PMC352004          DOI: 10.1128/AAC.11.3.441

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Comparative in vitro evaluation of BL-P1654 and carbenicillin against Pseudomonas.

Authors:  G D Overturf; R Ressler; J Wilkins
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

2.  Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods.

Authors:  J Klastersky; R Cappel; D Daneau
Journal:  Cancer       Date:  1973-02       Impact factor: 6.860

3.  Granulocytopenia associated with carbenicillin. Five episodes in two patients.

Authors:  M P Reyes; M Palutke; A M Lerner
Journal:  Am J Med       Date:  1973-03       Impact factor: 4.965

4.  Carbenicillin in treatment of severe infections due to pseudomonas.

Authors:  M C Jordan; H C Standiford; W M Kirby
Journal:  J Infect Dis       Date:  1970-09       Impact factor: 5.226

5.  The hemostatic defect produced by carbenicillin.

Authors:  C H Brown; E A Natelson; W Bradshaw; T W Williams; C P Alfrey
Journal:  N Engl J Med       Date:  1974-08-08       Impact factor: 91.245

6.  Carbenicillin-induced bleeding disorder.

Authors:  P D McClure; J G Casserly; C Monsier; D Crozier
Journal:  Lancet       Date:  1970-12-19       Impact factor: 79.321

Review 7.  Hematologic malignancies and other marrow failure states: progress in the management of complicating infections.

Authors:  A S Levine; S C Schimpff; R G Graw; R C Young
Journal:  Semin Hematol       Date:  1974-04       Impact factor: 3.851

8.  Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma.

Authors:  S C Schimpff; W H Greene; V M Young; P H Wiernik
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

9.  The carbenicillin-gentamicin combination against Pseudomonas aeruginosa. Correlation of effect with gentamicin sensitivity.

Authors:  R M Kluge; H C Standiford; B Tatem; V M Young; S C Schimpff; W H Greene; F M Calia; R B Hornick
Journal:  Ann Intern Med       Date:  1974-11       Impact factor: 25.391

10.  Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa.

Authors:  R M Kluge; H C Standiford; B Tatem; V M Young; W H Greene; S C Schimpff; F M Calia; R B Hornick
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

View more
  2 in total

1.  Quantitative assessment of bactericidal activities of beta-lactam antibiotics by agar plate method.

Authors:  G Masuda; S Tomioka
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

2.  In vitro activity of piperacillin compared with that of carbenicillin, ticarcillin, ampicillin, cephalothin, and cefamandole against Pseudomonas aeruginosa and Enterobacteriaceae.

Authors:  P P Shah; D J Briedis; H G Robson; J P Conterato
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.